AN OPEN-LABEL, PHASE 2 BASKET STUDY OF SEA-CD40 COMBINATION THERAPIES IN ADVANCED MALIGNANCIES

Registry ID

SGNS40-002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SEAGEN INC.

Start date

2021-11-13

Last update

2021-09-10

Conditions

• ADVANCED MALIGNANCIES

Related clinical trials

• A PHASE 1/1B FIRST-IN-HUMAN TRIAL OF BMS-986484 AS MONOTHERAPY AND COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES
• AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY OF SGN 35T IN ADULTS WITH ADVANCED MALIGNANCIES
• PHASE I/II STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY CLINICAL ACTIVITY OF BT8009 IN PATIENTS WITH NECTIN-4 EXPRESSING ADVANCED MALIGNANCIES
• AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE LB STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUS DELIVERY OF AMIVANTAMAB, A HUMAN BISPECIFIC EGFR AND CMET ANTIBODY FOR THE TREATMENT OF ADVANCED SOLID MALIGNANCIES
• CANADIAN ATEZOLIZUMAB PRECISION TARGETING FOR IMMUNOTHERAPY INTERVENTION: CAPTIV-8.
• A PHASE I/IB, OPEN-LABEL, MULTI-CENTER DOSE ESCALATION STUDY OF NIS793 IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES

View on source registry